Exosome & EV CDMO Services - Elise Biopharma

Exosome CDMO Services

From isolation to GMP manufacturing of exosomes and extracellular vesicles for next-generation therapeutics and diagnostics.

Overview

At Elise Biopharma, we provide end-to-end CDMO support for exosome and extracellular vesicle (EV) therapeutics, diagnostics, and delivery platforms. Exosomes are natural nanocarriers secreted by cells—highly stable, biocompatible, and capable of crossing biological barriers such as the blood–brain barrier. Their unique biology makes them powerful candidates for delivering nucleic acids, proteins, and small molecules, as well as regenerative therapies derived from stem cells.

Yet exosomes present some of the most challenging development and manufacturing hurdles in the industry: scalable production, reproducible isolation, purity from host cell contaminants, potency assays, and evolving regulatory frameworks. Elise Biopharma bridges this gap by combining cutting-edge upstream platforms, proprietary purification technologies, in-house analytics, and GMP aseptic fill-finish to help innovators bring exosome programs from discovery through clinical and commercial supply.

With Elise, you are not simply outsourcing manufacturing—you are partnering with a CDMO that understands the biology, engineering, and regulatory landscape of this rapidly advancing field.

Why Exosomes Matter

Exosomes are nature’s own nanocarriers—tiny vesicles evolved for precise, efficient intercellular communication. Unlike synthetic nanoparticles, which often face biocompatibility challenges, exosomes are built from endogenous lipids, proteins, and RNAs that allow them to fuse seamlessly with cell membranes and deliver functional cargo directly into target cells. Their lipid bilayer protects nucleic acids and proteins from degradation, while surface proteins guide uptake into specific tissues.

This natural sophistication is what makes exosomes one of the most promising therapeutic modalities of the next decade. Developers are advancing exosome programs across multiple frontiers:

Drug delivery vehicles – Exosomes can encapsulate siRNA, mRNA, CRISPR/Cas components, or small molecules, improving stability and enabling delivery across challenging barriers like the blood–brain barrier.
Regenerative medicine – Stem cell–derived exosomes carry growth factors, cytokines, and microRNAs that promote tissue repair, angiogenesis, wound healing, cartilage regeneration, and neuroprotection. They are being investigated for diseases ranging from myocardial infarction to Parkinson’s.
Immuno-oncology – Engineered exosomes can display tumor antigens or immune-modulatory ligands, priming immune responses without the complexity of whole-cell therapies. Exosomes can also deliver cytokine payloads directly into the tumor microenvironment.
Diagnostics & biomarkers – Circulating exosomes reflect the molecular signatures of their cell of origin, making them powerful non-invasive biomarkers for cancer, neurodegeneration, and infectious disease. Clinical assays are already moving toward FDA clearance.
Next-generation vaccines – Exosome-based vaccines can present antigens in their native membrane context, improving immunogenicity over synthetic formulations.

Clinical momentum is accelerating: the number of registered exosome clinical trials has more than doubled in the last five years, spanning neurology, oncology, cardiology, and infectious disease. Regulators are beginning to set standards for characterization, potency, identity, and safety, but guidance is still fragmented—creating both opportunity and risk. Few CDMOs have the infrastructure to consistently produce exosomes at GMP-grade, making Elise Biopharma’s dedicated platforms uniquely valuable to innovators who need to bridge discovery science and clinical translation.

A Trusted Partner for Exosome Innovators

Elise Biopharma partners with exosome developers across the ecosystem, tailoring support to each program’s stage and application:

Startups – Engineering exosome-based RNA and gene-editing delivery platforms, often seeking rapid translation from proof-of-concept to GMP clinical material.
Biopharma companies – Incorporating exosome carriers into established therapeutic pipelines to extend half-life, improve biodistribution, and reduce immunogenicity.
Regenerative medicine innovators – Scaling stem cell–derived exosome therapies for indications such as wound healing, osteoarthritis, cardiac repair, and CNS disorders.
Diagnostic developers – Isolating and validating exosomes as liquid biopsy biomarkers, and producing standardized vesicle preparations for diagnostic kit manufacturing.
Academic spinouts and translational centers – Moving early discoveries into Phase I/II clinical trials, requiring GMP-compliant production, fill-finish, and regulatory dossiers.
Platform companies – Building proprietary payload-loading, targeting, or purification technologies and needing a flexible CDMO partner to integrate these methods into scalable processes.

By combining upstream production, proprietary purification trains, and advanced analytics, Elise Biopharma provides exosome innovators with not just capacity, but a strategic partner who understands both the scientific nuance and the regulatory path ahead.

Our Exosome CDMO Capabilities

Upstream Production Platforms

We provide flexible systems for exosome and EV production at R&D through GMP scale:

Stem cell–derived exosomes – MSC, iPSC, or tissue-specific stem cells adapted to serum-free, chemically defined media.
Mammalian producer cell lines – HEK293, CHO, or custom-engineered cell lines designed for exosome payload loading.
Microbial/mixed systems – engineered bacteria or hybrid systems for specialty EVs.
Bioreactor-based production – 2 L to 2,000 L single-use systems with perfusion and digital-twin optimization for consistent vesicle yield.

Isolation & Purification

Exosome purification is one of the most critical steps. Elise Biopharma offers:

Tangential-flow filtration (TFF) – scalable concentration and diafiltration with optimized membrane cut-offs.
Ultracentrifugation alternatives – chromatography-based isolation (size-exclusion, ion exchange, affinity capture) for reproducibility and regulatory compliance.
Immunoaffinity capture – exosome subtype enrichment (e.g., tumor-specific EVs).
Proprietary polishing workflows – removal of protein aggregates, free nucleic acids, and host cell contaminants.

Analytical & QC Expertise

Robust analytics are essential for exosome characterization. Our in-house QC platform includes:

Particle sizing & counting – nanoparticle tracking analysis (NTA), dynamic light scattering (DLS), electron microscopy.
Surface marker profiling – Western blot, flow cytometry, ELISA for CD63, CD81, CD9, and custom markers.
Payload analysis – RNAseq, proteomics, and LC-MS for encapsulated cargo.
Potency assays – cell uptake, cytokine modulation, or tissue-specific activity.
Safety assays – endotoxin, sterility, mycoplasma, residual host DNA.
Stability studies – accelerated and long-term stability under ICH conditions.

Formulation & Fill-Finish

Exosomes require tailored formulation strategies to preserve vesicle integrity:

Liquid formulations – optimized buffer systems for stability at 2–8 °C.
Lyophilized exosomes – freeze-dried preparations for long-term storage and global distribution.
Encapsulation payload delivery – formulation with nucleic acids, proteins, or small molecules.
Aseptic fill-finish – vials, pre-filled syringes, or cartridges using Grade A robotic isolators.

Scale-Up & GMP Manufacturing

We ensure seamless scale-up for exosome programs:

Bench-scale – 2 L, 10 L R&D runs.
Pilot-scale – 50–200 L engineering batches.
GMP suites – 500–2,000 L production for clinical supply.
Commercial readiness – validated scale-down models, lifecycle management, supply chain and cold-chain logistics.

Regulatory & Clinical Support

The regulatory landscape for exosomes is still evolving. Elise Biopharma provides:

CMC documentation aligned with FDA, EMA, PMDA frameworks for novel biologics.
Assay validation for identity, purity, potency, and safety.
Stage-appropriate documentation – early-phase exploratory filings through to late-stage dossiers.
Global regulatory support – experience with exosome filings for regenerative medicine and oncology.
Quality systems – full traceability and QMS aligned with ICH Q5/Q6, ISO 13485, and emerging EV standards.

Innovation & Differentiation

Elise Biopharma differentiates itself by offering:

Advanced bioreactor platforms for scalable exosome production.
Proprietary purification trains designed for regulatory-grade reproducibility.
Digital analytics integration – real-time particle characterization and QC dashboards.
Payload engineering expertise – custom strategies for RNA, protein, or drug encapsulation.
End-to-end integration – discovery support, process development, GMP manufacturing, QC, and regulatory guidance in one partner.

Why Innovators Choose Elise Biopharma

Clients choose Elise because we combine:

Deep scientific expertise in exosome biology and manufacturing.
Flexible infrastructure for programs from early R&D to commercial scale.
Specialized QC platforms tailored for vesicle analytics.
Regulatory foresight in a rapidly evolving field.
Global readiness for trial deployment and commercial supply.

Whether you’re developing exosomes as RNA delivery vehicles, stem cell–derived regenerative therapies, or biomarker-driven diagnostics, Elise Biopharma provides the scale, rigor, and partnership to make your program succeed.

Exosomes and EVs are poised to transform drug delivery, regenerative medicine, and oncology. But their complexity demands a CDMO with specialized expertise in vesicle biology, scalable production, purification, and analytics. Elise Biopharma provides that foundation—helping you transform discovery into clinical and commercial reality.’

Learn more about Exosomes in our blog post here: The 10 Essentials Every Great Exosome CDMO Must Deliver

Contact us today to discuss your exosome project and explore how Elise Biopharma can accelerate your path to patients.

Email your questions or Exosome project needs to info@elisebiopharma.com